Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy

Cancer

Volumn 118, Issue 12, 2012, Pages 3071-3078

  Ahmed, Hashim Uddin ^a,b,f   Cathcart, Paul ^b,c   Chalasani, Venu ^c   Williams, Andrew ^d   McCartan, Neil ^a,b   Freeman, Alex ^e   Kirkham, Alex ^c   Allen, Clare ^c   Chin, Joseph ^c   Emberton, Mark ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASTRO PHOENIX CRITERIA; BLADDER NECK STENOSIS; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL ASSESSMENT; CLINICAL CLASSIFICATION; CYSTOSCOPY; EPIDIDYMITIS; EXTERNAL BEAM RADIOTHERAPY; FISTULA; GLEASON SCORE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION 5 POINT SCORE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MODIFIED CLAVIEN SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; OSTEITIS PUBIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; RAND SF 36 SCORE; RECTOURETHRAL FISTULA; RETREATMENT; SCORING SYSTEM; SHORT FORM 36; TREATMENT RESPONSE; ULTRASOUND THERAPY; URINARY TRACT INFECTION; WHOLE GLAND SALVAGE HIGH INTENSITY ULTRASOUND THERAPY;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RETREATMENT; SALVAGE THERAPY; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84861858804     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26631     Document Type: Article

References (30)

1. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multiinstitutional pooled analysis. JAMA. 1999;281:1598-1604. (Pubitemid 29211768)
2. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327-333. (Pubitemid 46108308)
3. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol. 2004;171:1132-1136. (Pubitemid 38327542)
4. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR; Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: Likelihood, patterns of care, and outcomes. Cancer. 2008;112:307-314.
5. Touma NJ, Izawa JI, Chin JL. Current status of local salvage therapies following radiation failure for prostate cancer. J Urol. 2005;173:373-379.
6. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110:1417-1428. (Pubitemid 47463054)
7. Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010;105:191-201.
8. Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS and Carroll PR. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: Data from cancer of the prostate strategic urologic research endeavor. J Urol. 2002;168:530-535. (Pubitemid 34793288)
9. Grossfeld GD, Li YP, P Lubeck DP and Carroll PR. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology. 2002;60:57-62.
10. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388-2399.
11. Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer. 2009;101:19-26.
12. Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, Walter B. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology. 2008;72:1329-1333.
13. Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Murota A, Nagata Y. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int J Urol. 2009;16:881-886.
14. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C, Emberton M. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int. 2008;102:786-792.
15. Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M. Visually directed HIFU for organ confined prostate cancer - a proposed standard for the conduct of therapy. BJU Int. 2006;98:1187-1192. (Pubitemid 44721222)
16. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Medical Care. 1998;36:1002-1012. (Pubitemid 128456439)
17. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF) a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822-830. (Pubitemid 27246947)
18. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Economics. 1993;2:217-227.
19. Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111:518-526.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of surgery. Ann Surg. 2004;240:205-213. (Pubitemid 38963009)
21. Chalasani V, Martinez CH, Lim D, Chin J. Salvage HIFU for recurrent prostate cancer after radiotherapy. Prostate Cancer Prostatic Dis. 2009;12:124-129.
22. Zacharakis E, Ahmed HU, Ishaq A, et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int. 2008;102:786-792.
23. Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY, Gelet A. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radio-recurrent prostate cancer. Eur Urol. 2009;55:640-647.
24. Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouvière O, Curiel L, Janier M, Vallancien G. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology. 2004;63:625-629. (Pubitemid 38479395)
25. Berge V, Baco E, Karlsen SJ. A prospective study of salvage highintensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scand J Urol Nephrol. 2010;44:223-227.
26. Challacombe BJ, Murphy DG, Zakri R, Cahill DJ. High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up. BJU Int. 2009;104:200-204.
27. Arumainayagam N, Kumaar S, Ahmed HU, Moore CM, Payne H, Freeman A, Allen C, Kirkham A, Emberton M. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int. 2010;106:991-997.
28. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51-60.
29. Roach M 3rd. Primary focal unilateral nerve-sparing cryoablation for very early prostate cancer: is it enough or too much, or do we know? Cancer J. 2010;16:542-543.
30. de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, Frauscher F, Greene D, Harisinghani M, Haustermans K, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24:775-780.